Taylor Ben R 4

What Happened
Ben R. Taylor, Chief Financial Officer of Recursion Pharmaceuticals (RXRX), disposed of a total of 15,031 shares across two transactions. On 2026-03-16, 7,075 shares were withheld to satisfy tax withholding on a net settlement of restricted stock units (7,075 @ $3.42 = $24,197). On 2026-03-17, 7,956 shares were sold in the open market under a Rule 10b5-1 plan (7,956 @ $3.39 = $26,971). Combined proceeds were about $51,168. These were sales—routine tax withholding plus a scheduled plan sale—not purchases.

Key Details

• Transaction dates and prices:
  • 2026-03-16: 7,075 shares withheld for tax (F) at $3.42 — $24,197
  • 2026-03-17: 7,956 shares sold open market (S) at $3.39 — $26,971
• Total shares disposed: 15,031; approximate total value: $51,168.
• Shares owned after the transactions: not specified in the provided filing excerpt (see the filed Form 4 for post-transaction holdings).
• Footnotes:
  • F1: Withheld shares to satisfy issuer tax withholding on net-settled restricted stock units.
  • F2: The open-market sale was made pursuant to a Rule 10b5-1 trading plan adopted Sept 30, 2025.
• Filing/timeliness: Form 4 was filed on 2026-03-18 covering transactions on 2026-03-16/17 — appears timely (not marked late).

Context

• The F-code transaction reflects tax withholding on RSUs (a common, administrative disposition when awards vest).
• The S-code sale was executed under a pre-established 10b5-1 plan, which schedules trades and reduces the likelihood the sale was based on nonpublic information.
• Sales do not necessarily indicate negative views about the company; these events here are routine (tax withholding and a planned sale).